Literature DB >> 1726071

Presynaptic dopaminergic neurotransmission mediates amphetamine-induced unconditioned but not amphetamine-conditioned locomotion and defecation in the rat.

S L Di Lullo1, M T Martin-Iverson.   

Abstract

A series of experiments were conducted to investigate the role of presynaptic dopamine (DA) and noradrenaline (NA) neurotransmission in stimulant-unconditioned and conditioned locomotion and defecation. (+)-Amphetamine (AMP, 1.5 mg/kg, s.c.) increased both locomotion and defecation in rats, and both of these effects were conditioned to environmental stimuli. Some groups of rats were treated with DSP4 (50 mg/kg, i.p.), a selective, long-lasting NA neurotoxin, given 7 days prior to conditioning with AMP. This treatment depleted forebrain NA to between 1% and 54% of control levels, depending on the brain region, but did not attenuate either AMP-unconditioned or conditioned locomotion. These results indicate that NA does not mediate either AMP unconditioned or conditioned locomotion. alpha-Methyl-para-tyrosine methyl ester (alpha MPT, 25-50 mg/kg, s.c.), a selective inhibitor of catecholamine synthesis given during conditioning with AMP, attenuated unconditioned AMP-induced locomotion and defecation but did not influence AMP-conditioned locomotion and defecation. Thus, alpha MPT blocked AMP-induced unconditioned locomotion, supporting the hypothesis that the locomotor and defecation stimulant effects of AMP are mediated by DA release. In spite of the attenuation of the direct effects of AMP, alpha MPT did not attenuate AMP-conditioned locomotion or defecation. It is concluded that AMP-induced release of dopamine is responsible for the unconditioned behavioral effects of amphetamine but not for the conditioning of amphetamine-induced locomotion and defecation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726071     DOI: 10.1016/0006-8993(91)91377-d

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.

Authors:  Sanders A McDougall; Rita M Hernandez; Carmela M Reichel; Cristal M Farley
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

2.  Conditioning versus priming of dopaminergic grafts by amphetamine.

Authors:  L E Annett; P J Reading; D Tharumaratnam; D N Abrous; E M Torres; S B Dunnett
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

3.  Reduced presynaptic dopamine activity in adolescent dorsal striatum.

Authors:  Marguerite Matthews; Corina Bondi; Gonzalo Torres; Bita Moghaddam
Journal:  Neuropsychopharmacology       Date:  2013-01-28       Impact factor: 7.853

4.  Effects of nimodipine and/or haloperidol on the expression of conditioned locomotion and sensitization to cocaine in rats.

Authors:  M T Martin-Iverson; A R Reimer
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

Review 5.  Behavioral sensitization and tolerance to cocaine and the occupation of dopamine receptors by dopamine.

Authors:  M T Martin-Iverson; L Y Burger
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

6.  Effects of dopamine and serotonin synthesis inhibitors on the ketamine-, d-amphetamine-, and cocaine-induced locomotor activity of preweanling and adolescent rats: sex differences.

Authors:  Sanders A McDougall; Jasmine W Rios; Matthew G Apodaca; Ginny I Park; Nazaret R Montejano; Jordan A Taylor; Andrea E Moran; Jasmine A M Robinson; Timothy J Baum; Angie Teran; Cynthia A Crawford
Journal:  Behav Brain Res       Date:  2019-10-23       Impact factor: 3.332

7.  Nimodipine and haloperidol attenuate behavioural sensitization to cocaine but only nimodipine blocks the establishment of conditioned locomotion induced by cocaine.

Authors:  A R Reimer; M T Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.